Feature Dimension Maps for Visual Attention

Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Santa Barbara
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

How does one know what to look at in a scene? Imagine a "Where's Waldo" game - it's challenging to find Waldo because there are many 'salient' locations in the picture, each vying for one's attention. One can only attend to a small location on the picture at a given moment, so to find Waldo, one needs to direct their attention to different locations. One prominent theory about how one accomplishes this claims that important locations are identified based on distinct feature types (for example, motion or color), with locations most unique compared to the background most likely to be attended. An important component of this theory is that individual feature dimensions (again, color or motion) are computed within their own 'feature maps', which are thought to be implemented in specific brain regions. However, whether and how specific brain regions contribute to these feature maps remains unknown.

The goal of this study is to determine how brain regions that respond strongly to different feature types (color and motion) and which encode spatial locations of visual stimuli transform 'feature dimension maps' based on stimulus properties as a function of task instructions. The investigators hypothesize that feature-selective brain regions act as neural feature dimension maps, and thus encode representations of relevant location(s) based on their preferred feature dimension, such that the stimulus representation in the most relevant feature map is up-regulated to support adaptive behavior. The investigators will scan healthy human participants using functional MRI (fMRI) in a repeated-measures design while they view visual stimuli made relevant based on a cued feature dimension (e.g., color or motion). The investigators will employ state-of-the-art multivariate analysis techniques that allow them to reconstruct an 'image' of the stimulus representation encoded by each brain region to dissect how neural tissue identifies salient locations. Each participant will perform a challenging discrimination task based on the cued feature (report motion direction or color of stimulus dots) of either a single stimulus presented in the periphery, which are identical across trial types, or multiple simultaneously-presented stimuli. Across trials the investigators will manipulate the attended feature value (color, motion, or fixation point) and number of attended stimuli (attend 1 stimulus, attend 2 stimuli). These manipulations will help the investigators fully understand these critical relevance computations in the healthy human visual system.

Who Is on the Research Team?

TC

Tommy C Sprague

Principal Investigator

University of California, Santa Barbara

Are You a Good Fit for This Trial?

This study is for healthy adults aged 18 to 55 who have normal or corrected-to-normal vision. People with significant health issues or vision problems that can't be corrected are not eligible.

Inclusion Criteria

I am between 18 and 55 years old.
My vision is normal or corrected to normal with glasses or contacts.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Anatomical & Retinotopic Mapping

Participants undergo anatomical and retinotopic mapping to identify brain regions for further analysis

2 hours
1 visit (in-person)

Experimental fMRI Sessions

Participants engage in visual attention tasks during fMRI scanning to study feature dimension maps

3-4 hours
2 visits (in-person)

Follow-up

Participants are monitored for any post-experiment effects and data analysis is conducted

1-2 weeks

What Are the Treatments Tested in This Trial?

Trial Overview

Researchers are using fMRI scans to see how the brain processes visual information, like color and motion, during attention tasks. Participants will look at moving dots and report on their color or direction while their brain activity is measured.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Manipulations of task demands and attended location(s) (Expt 2.2)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Santa Barbara

Lead Sponsor

Trials
33
Recruited
3,100+

National Eye Institute (NEI)

Collaborator

Trials
572
Recruited
1,320,000+